To understand the characteristics, management, and outcomes of patients with fulminant myocarditis treated with temporary mechanical circulatory support (tMCS), highlighting its significance in critical care.
Key Findings:
One-year mortality was 36%; 44% experienced death, heart transplantation, or durable LVAD, indicating high-risk outcomes.
VA-ECMO was the predominant tMCS strategy, used in nearly two-thirds of patients, suggesting a need for evaluation of alternative strategies.
31% of cases were diagnosed on clinical grounds alone, highlighting a diagnostic gap that needs addressing.
Less than half of the cohort received immunomodulation, with unclear timing and efficacy, raising questions about treatment protocols.
Biopsies performed after 2 days were associated with worse outcomes, but this may be influenced by selection and timing biases, necessitating further investigation.
Interpretation:
The study provides high-quality, prospective data but raises questions about optimal device use, timing of support initiation, and the role of immunotherapy, indicating a need for further research.
Limitations:
Lack of standardized definitions and long-term outcomes in existing literature limits the applicability of findings.
Potential biases in biopsy timing and patient selection may affect the reliability of results.
Competing risks and variable follow-up timing complicate outcome interpretation, necessitating careful consideration in future studies.
Conclusion:
The study enhances understanding of tMCS in fulminant myocarditis but leaves critical questions regarding device selection, timing, and patient stratification unanswered, emphasizing the need for future research.
